Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

This study evaluated the efficacy and safety of topical GT20029 in 180 Chinese adult males with androgenetic alopecia over 12 weeks. Participants were divided into six groups receiving either 0.5% or 1.0% GT20029 or a placebo, administered once daily or twice weekly. Results showed significant increases in target area non-vellus hair count (TAHC) for all GT20029-treated groups at Week 12, with the 0.5% QD and 1.0% BIW groups showing notable improvements over placebo (p=0.032 and p=0.023, respectively). Hair width also improved significantly in the 1.0% BIW group compared to placebo (p=0.011). The incidence of treatment-emergent adverse events was similar across all groups and mostly mild. The study concluded that topical GT20029 is effective in promoting hair regrowth with good tolerability, suggesting further research to confirm its potential as a treatment for androgenetic alopecia.